Clinton Group’s Amphastar Pharmaceuticals AMPH Stock Holding History

Clinton Group’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-33,305	Closed	-$483K	–	559
2017 Q1	$483K	Buy	33,305 +17,416	+110%	+$274K	0.03%	636
2016 Q4	$293K	Buy	+15,889	New	+$309K	0.02%	700

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Clinton Group's AMPH Position: Q2 2017 in Review

Clinton Group sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2017, closing a stake of 33,305 shares — an estimated $483K sold.

Clinton Group first reported a position in AMPH in Q4 2016 and held it in 2 quarters. The position peaked at $483K in Q1 2017. 108 funds tracked by Wall St. Rank hold AMPH as of Q2 2017.

Clinton Group reported no remaining Amphastar Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Clinton Group sold 33,305 Amphastar Pharmaceuticals shares in Q2 2017, an estimated $483K.
Clinton Group first reported a position in Amphastar Pharmaceuticals in Q4 2016 and held it in 2 quarters.
Clinton Group's Amphastar Pharmaceuticals position peaked at $483K in Q1 2017.
108 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2017.

Based on Clinton Group's 13F filing for Q2 2017, filed 14 Aug 2017.